|
|
|
|
|
 |
Dental Patients
|
|
| |
|
GEM 21S® Growth-factor Enhanced Matrix
The Company's first product, GEM 21S, has been approved by the Food & Drug Administration (FDA)and Health Canada for the treatment of bone loss and gum tissue recession associated with advanced periodontal disease. GEM 21S combines the tissue growth factor, recombinant human Platelet-Derived Growth Factor (rhPDGF-BB)with the synthetic bone matrix, Beta-tricalcium phosphate (β-TCP).
The β-TCP component of GEM 21S physically fills bone defects providing a biocompatible scaffold or matrix that facilitates new bone formation while the rhPDGF actively promotes the growth of new bone into the treatment site through the direct stimulation of osteoblasts, or bone forming cells.
Under an exclusive agreement with Osteohealth Company, a division of Luitpold Pharmaceuticals, Inc. which is a group company of Sankyo Co., Ltd., Osteohealth is responsible for the worldwide marketing, sales, distribution, and post-approval development of GEM 21S. Clinicians should contact Osteohealth directly for additional product information.
To learn more about GEM 21S, please click on one of the topics below:
|
| |
|
| |
|
|
| |
 |
|
|
| |
| |
|
|
|
|
|
